An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

BACKGROUND: Epidemic outbreaks caused by SARS-CoV-2 are worsening around the world, and there are no target drugs to treat COVID-19. IFN-κ inhibits the replication of SARS-CoV-2; and TFF2 is a small secreted polypeptide that promotes the repair of mucosal injury and reduces the inflammatory response...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Weihui, Liu, Yan, Liu, Li, Hu, Huiliang, Cheng, Xiaobo, Liu, Ping, Song, Zhigang, Zha, Lijun, Bai, Shimeng, Xu, Tingting, Yuan, Songhua, Lu, Fengru, Shang, Zhiying, Zhao, Yihong, Wang, Jing, Zhao, Jun, Ding, Longfei, Chen, Jun, Zhang, Lin, Zhu, Tongyu, Zhang, Xiaoyan, Lu, Hongzhou, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502282/
https://www.ncbi.nlm.nih.gov/pubmed/32984784
http://dx.doi.org/10.1016/j.eclinm.2020.100547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502282/
https://www.ncbi.nlm.nih.gov/pubmed/32984784
http://dx.doi.org/10.1016/j.eclinm.2020.100547

Ejemplares similares